20/20 Biolabs (AIDX) Competitors

$1.49 -0.03 (-1.97%)

Closing price 04:00 PM Eastern

Extended Trading

$1.54 +0.05 (+3.36%)

As of 05:24 PM Eastern

AIDX vs. FORA, ONMD, WKEY, MNY, and GMHS

Should you be buying 20/20 Biolabs stock or one of its competitors? The main competitors of 20/20 Biolabs include Forian (FORA), OneMedNet (ONMD), WISeKey International (WKEY), MoneyHero (MNY), and Gamehaus (GMHS). These companies are all part of the "business services" industry.

How does 20/20 Biolabs compare to Forian?

20/20 Biolabs (NASDAQ:AIDX) and Forian (NASDAQ:FORA) are both small-cap business services companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, valuation, risk, dividends, analyst recommendations and institutional ownership.

: 20/20 Biolabs has higher earnings, but lower revenue than Forian.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
20/20 Biolabs $2.05M 7.64 N/A N/A N/A
Forian $30.26M 2.22 -$2.81M -$0.09 N/A
: 19.3% of Forian shares are held by institutional investors. 24.8% of Forian shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
: Company Net Margins Return on Equity Return on Assets
20/20 Biolabs N/A N/A N/A
Forian N/A N/A N/A
: In the previous week, Forian had 2 more articles in the media than 20/20 Biolabs. MarketBeat recorded 2 mentions for Forian and 0 mentions for 20/20 Biolabs. Forian's average media sentiment score of 0.96 beat 20/20 Biolabs' score of 0.00 indicating that Forian is being referred to more favorably in the news media.
Company Overall Sentiment
20/20 Biolabs Neutral
Forian Positive
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
20/20 Biolabs
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Forian
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
20/20 Biolabs	$2.05M	7.64	N/A	N/A	N/A
Forian	$30.26M	2.22	-$2.81M	-$0.09	N/A

Company	Net Margins	Return on Equity	Return on Assets
20/20 Biolabs	N/A	N/A	N/A
Forian	N/A	N/A	N/A

Company	Overall Sentiment
20/20 Biolabs	Neutral
Forian	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
20/20 Biolabs	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Forian	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Forian beats 20/20 Biolabs on 6 of the 7 factors compared between the two stocks.

How does 20/20 Biolabs compare to OneMedNet?

20/20 Biolabs (NASDAQ:AIDX) and OneMedNet (NASDAQ:ONMD) are both small-cap business services companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, valuation, risk, dividends, analyst recommendations and institutional ownership.

: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
20/20 Biolabs
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
OneMedNet
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: 20/20 Biolabs has higher revenue and earnings than OneMedNet.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
20/20 Biolabs $2.05M 7.64 N/A N/A N/A
OneMedNet $1.36M 38.23 -$2.80M -$0.07 N/A
: 1.0% of OneMedNet shares are held by institutional investors. 46.2% of OneMedNet shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
: 20/20 Biolabs has a net margin of 0.00% compared to OneMedNet's net margin of -205.96%.
Company Net Margins Return on Equity Return on Assets
20/20 Biolabs N/A N/A N/A
OneMedNet -205.96% N/A -355.73%
: In the previous week, OneMedNet had 1 more articles in the media than 20/20 Biolabs. MarketBeat recorded 1 mentions for OneMedNet and 0 mentions for 20/20 Biolabs. OneMedNet's average media sentiment score of 1.86 beat 20/20 Biolabs' score of 0.00 indicating that OneMedNet is being referred to more favorably in the news media.
Company Overall Sentiment
20/20 Biolabs Neutral
OneMedNet Very Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
20/20 Biolabs	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
OneMedNet	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
20/20 Biolabs	$2.05M	7.64	N/A	N/A	N/A
OneMedNet	$1.36M	38.23	-$2.80M	-$0.07	N/A

Company	Net Margins	Return on Equity	Return on Assets
20/20 Biolabs	N/A	N/A	N/A
OneMedNet	-205.96%	N/A	-355.73%

Company	Overall Sentiment
20/20 Biolabs	Neutral
OneMedNet	Very Positive

Summary

OneMedNet beats 20/20 Biolabs on 6 of the 9 factors compared between the two stocks.

How does 20/20 Biolabs compare to WISeKey International?

WISeKey International (NASDAQ:WKEY) and 20/20 Biolabs (NASDAQ:AIDX) are both small-cap business services companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations.

: 20/20 Biolabs has lower revenue, but higher earnings than WISeKey International.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
WISeKey International $19.29M 2.99 -$6.07M N/A N/A
20/20 Biolabs $2.05M 7.64 N/A N/A N/A
: In the previous week, WISeKey International had 5 more articles in the media than 20/20 Biolabs. MarketBeat recorded 5 mentions for WISeKey International and 0 mentions for 20/20 Biolabs. WISeKey International's average media sentiment score of 0.80 beat 20/20 Biolabs' score of 0.00 indicating that WISeKey International is being referred to more favorably in the media.
Company Overall Sentiment
WISeKey International Positive
20/20 Biolabs Neutral
: Company Net Margins Return on Equity Return on Assets
WISeKey International N/A N/A N/A
20/20 Biolabs N/A N/A N/A
: WISeKey International presently has a consensus target price of $10.50, indicating a potential upside of 48.73%. Given WISeKey International's stronger consensus rating and higher possible upside, analysts plainly believe WISeKey International is more favorable than 20/20 Biolabs.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
WISeKey International
1 Sell rating(s)
0 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.33
20/20 Biolabs
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: 0.3% of WISeKey International shares are owned by institutional investors. 33.5% of WISeKey International shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
WISeKey International	$19.29M	2.99	-$6.07M	N/A	N/A
20/20 Biolabs	$2.05M	7.64	N/A	N/A	N/A

Company	Overall Sentiment
WISeKey International	Positive
20/20 Biolabs	Neutral

Company	Net Margins	Return on Equity	Return on Assets
WISeKey International	N/A	N/A	N/A
20/20 Biolabs	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
WISeKey International	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
20/20 Biolabs	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

WISeKey International beats 20/20 Biolabs on 8 of the 9 factors compared between the two stocks.

How does 20/20 Biolabs compare to MoneyHero?

MoneyHero (NASDAQ:MNY) and 20/20 Biolabs (NASDAQ:AIDX) are both small-cap business services companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

: 20/20 Biolabs has a net margin of 0.00% compared to MoneyHero's net margin of -7.05%. 20/20 Biolabs' return on equity of 0.00% beat MoneyHero's return on equity.
Company Net Margins Return on Equity Return on Assets
MoneyHero -7.05% -12.31% -6.76%
20/20 Biolabs N/A N/A N/A
: MoneyHero presently has a consensus target price of $4.00, suggesting a potential upside of 181.69%. Given MoneyHero's stronger consensus rating and higher possible upside, equities research analysts plainly believe MoneyHero is more favorable than 20/20 Biolabs.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MoneyHero
1 Sell rating(s)
1 Hold rating(s)

0 Buy rating(s)

1 Strong Buy rating(s)
2.33
20/20 Biolabs
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: 20/20 Biolabs has lower revenue, but higher earnings than MoneyHero.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
MoneyHero $73.43M 0.81 -$5.18M -$0.20 N/A
20/20 Biolabs $2.05M 7.64 N/A N/A N/A
: In the previous week, MoneyHero had 6 more articles in the media than 20/20 Biolabs. MarketBeat recorded 6 mentions for MoneyHero and 0 mentions for 20/20 Biolabs. MoneyHero's average media sentiment score of 0.99 beat 20/20 Biolabs' score of 0.00 indicating that MoneyHero is being referred to more favorably in the media.
Company Overall Sentiment
MoneyHero Positive
20/20 Biolabs Neutral
: 30.9% of MoneyHero shares are held by institutional investors. 19.2% of MoneyHero shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
MoneyHero	-7.05%	-12.31%	-6.76%
20/20 Biolabs	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MoneyHero	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
20/20 Biolabs	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MoneyHero	$73.43M	0.81	-$5.18M	-$0.20	N/A
20/20 Biolabs	$2.05M	7.64	N/A	N/A	N/A

Company	Overall Sentiment
MoneyHero	Positive
20/20 Biolabs	Neutral

Summary

MoneyHero beats 20/20 Biolabs on 8 of the 12 factors compared between the two stocks.

How does 20/20 Biolabs compare to Gamehaus?

Gamehaus (NASDAQ:GMHS) and 20/20 Biolabs (NASDAQ:AIDX) are both small-cap business services companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment, risk and earnings.

: In the previous week, Gamehaus had 1 more articles in the media than 20/20 Biolabs. MarketBeat recorded 1 mentions for Gamehaus and 0 mentions for 20/20 Biolabs. Gamehaus' average media sentiment score of 1.92 beat 20/20 Biolabs' score of 0.00 indicating that Gamehaus is being referred to more favorably in the media.
Company Overall Sentiment
Gamehaus Very Positive
20/20 Biolabs Neutral
: 63.7% of Gamehaus shares are held by institutional investors. 27.7% of Gamehaus shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
: Gamehaus has higher revenue and earnings than 20/20 Biolabs.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Gamehaus $118.05M 0.44 $3.96M $0.09 10.78
20/20 Biolabs $2.05M 7.64 N/A N/A N/A
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gamehaus
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
20/20 Biolabs
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: Company Net Margins Return on Equity Return on Assets
Gamehaus N/A N/A N/A
20/20 Biolabs N/A N/A N/A

Company	Overall Sentiment
Gamehaus	Very Positive
20/20 Biolabs	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gamehaus	$118.05M	0.44	$3.96M	$0.09	10.78
20/20 Biolabs	$2.05M	7.64	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gamehaus	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
20/20 Biolabs	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Net Margins	Return on Equity	Return on Assets
Gamehaus	N/A	N/A	N/A
20/20 Biolabs	N/A	N/A	N/A

Summary

Gamehaus beats 20/20 Biolabs on 6 of the 7 factors compared between the two stocks.

Get 20/20 Biolabs News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AIDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AIDX vs. The Competition

Export

Metric	20/20 Biolabs	Services – Research, Development, Testing Labs Industry	Services Sector	NASDAQ Exchange
Market Cap	$15.62M	$11.83M	$1.01B	$11.87B
Dividend Yield	N/A	N/A	4.63%	5.21%
P/E Ratio	N/A	N/A	15.71	28.47
Price / Sales	7.64	4.59	23.03	60.92
Price / Cash	N/A	N/A	34.66	36.52
Price / Book	N/A	0.33	6.59	6.67
Net Income	N/A	-$15.16M	$1.76M	$332.53M
7 Day Performance	-3.86%	-3.98%	1.05%	2.01%
1 Month Performance	-18.58%	-14.65%	41.77%	9.19%
1 Year Performance	N/A	N/A	-6.46%	39.59%

20/20 Biolabs Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AIDX 20/20 Biolabs	N/A	$1.49 -2.0%	N/A	N/A	$15.62M	$2.05M	N/A	14
FORA Forian	0.8591 of 5 stars	$2.16 +0.5%	N/A	N/A	$67.41M	$30.26M	N/A	140	Positive News
ONMD OneMedNet	1.5299 of 5 stars	$1.20 +8.6%	N/A	N/A	$62.38M	$1.36M	N/A	2	Positive News Gap Up
WKEY WISeKey International	2.0833 of 5 stars	$7.01 -2.5%	$10.50 +49.8%	N/A	$57.29M	$11.88M	N/A	140	News Coverage
MNY MoneyHero	2.3318 of 5 stars	$1.35 -0.4%	$4.00 +197.4%	N/A	$56.37M	$79.51M	N/A	359	Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AIDX) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

20/20 Biolabs (AIDX) Competitors

AIDX vs. FORA, ONMD, WKEY, MNY, and GMHS

How does 20/20 Biolabs compare to Forian?

Summary

How does 20/20 Biolabs compare to OneMedNet?

Summary

How does 20/20 Biolabs compare to WISeKey International?

Summary

How does 20/20 Biolabs compare to MoneyHero?

Summary

How does 20/20 Biolabs compare to Gamehaus?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AIDX vs. The Competition

20/20 Biolabs Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

20/20 Biolabs (AIDX) Competitors

AIDX vs. FORA, ONMD, WKEY, MNY, and GMHS

How does 20/20 Biolabs compare to Forian?

Summary

How does 20/20 Biolabs compare to OneMedNet?

Summary

How does 20/20 Biolabs compare to WISeKey International?

Summary

How does 20/20 Biolabs compare to MoneyHero?

Summary

How does 20/20 Biolabs compare to Gamehaus?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AIDX vs. The Competition

20/20 Biolabs Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools